SCHEMBL893056

SCHEMBL893056

CCOC(=O)c1noc(-c2ccccc2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.57
HDAC6 Q9UBN7 2/20 0.57
HDAC8 Q9BY41 1/20 0.57
TARBP2 Q15633 1/20 0.56
ALDH1A1 P00352 6/20 0.55
KDM4E B2RXH2 4/20 0.55
HPGD P15428 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
LMNA P02545 2/20 0.55
MAPT P10636 2/20 0.55
RAB9A P51151 2/20 0.55
NPC1 O15118 1/20 0.55
GAA P10253 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
KMT2A Q03164 2/20 0.53
HSD17B10 Q99714 2/20 0.53
MMP2 P08253 1/20 0.50
BMP1 P13497 1/20 0.50
CDC7 O00311 1/20 0.50
TRPM8 Q7Z2W7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzoyl Chloride SCHEMBL1703592 0.91 HDAC1 (0.49) HDAC1HDAC6HDAC8TARBP2ALDH1A1
SCHEMBL11509023 0.90 ALDH1A1 (0.48) HDAC1HDAC6HDAC8TARBP2ALDH1A1
SCHEMBL8825537 0.87 CDC7 (0.51) TARBP2ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL3108887 0.86 NPC1 (0.49) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL8825390 0.86 ALDH1A1 (0.53) HDAC1HDAC6HDAC8TARBP2ALDH1A1
SCHEMBL8341931 0.86 TARBP2 (0.60) TARBP2ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL8825436 0.85 NPC1 (0.52) ALDH1A1KDM4EHPGDSMN1; SMN2LMNA
SCHEMBL8825404 0.85 ALDH1A1 (0.52) HDAC1HDAC6HDAC8TARBP2ALDH1A1
SCHEMBL8825172 0.85 ALDH1A1 (0.75) TARBP2ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL5958307 0.84 TRPM8 (0.56) SMN1; SMN2MAPTRAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3713934-B1 OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF GENETIC DISEASES DUE TO NONSENSE MUTATIONS UNIV DEGLI STUDI DI PALERMO (IT) 2022-04-13 EP claimed
US-11203578-B2 Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations UNIVERSITA'DEGLI STUDI DIPALERMO (IT) 2021-12-21 US claimed
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed
US-11834452-B2 CXCR7 antagonists CHEMOCENTRYX, INC. (US) 2023-12-05 US disclosed
US-11834452-B2 CXCR7 antagonists CHEMOCENTRYX, INC. (US) 2023-12-05 US disclosed
US-20220127272-A1 CXCR7 ANTAGONISTS CHEMOCENTRYX, INC. 2022-04-28 US disclosed
US-11203578-B2 Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations UNIVERSITA'DEGLI STUDI DIPALERMO (IT) 2021-12-21 US disclosed
US-11203578-B2 Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations UNIVERSITA'DEGLI STUDI DIPALERMO (IT) 2021-12-21 US disclosed
US-11059825-B2 CXCR7 antagonists CHEMOCENTRYX, INC. (US) 2021-07-13 US disclosed
US-9169261-B2 CXCR7 antagonists CHEMOCENTRYX, INC. (US) 2015-10-27 US disclosed
US-20140154179-A1 CXCR7 ANTAGONISTS CHEMOCENTRYX, INC. (US) 2014-06-05 US disclosed
WO-2014085490-A1 CXCR7 ANTAGONISTS CHEMOCENTRYX, INC. (US) 2014-06-05 WO disclosed
US-20140154179-A1 CXCR7 ANTAGONISTS CHEMOCENTRYX, INC. (US) 2014-06-05 US disclosed
US-20140066457-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND (BE) 2014-03-06 US disclosed
US-8618138-B2 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2013-12-31 US disclosed
EP-2440550-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2012-04-18 EP disclosed
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-04-05 US disclosed
WO-2010142801-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083475-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN HDAC1 2284/4885HDAC6 109/4885HDAC8 1575/4885
US-20140066457-A1 INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, MAPT, NLN HDAC1 2216/4885HDAC6 108/4885HDAC8 1584/4885
US-11203578-B2 Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations UPF1, OXA1L, RNMT HDAC1 1141/4885HDAC6 1352/4885HDAC8 1880/4885
US-11059825-B2 CXCR7 antagonists CXCR1, CXCR5, CCR7 HDAC1 1101/4885HDAC6 738/4885HDAC8 1812/4885
US-11834452-B2 CXCR7 antagonists CXCR1, CXCR5, CCR7 HDAC1 1101/4885HDAC6 738/4885HDAC8 1812/4885
US-20140154179-A1 CXCR7 ANTAGONISTS CXCR1, CXCR5, CCR7 HDAC1 1101/4885HDAC6 738/4885HDAC8 1812/4885
US-20220127272-A1 CXCR7 ANTAGONISTS CXCR1, CXCR5, CCR7 HDAC1 1101/4885HDAC6 738/4885HDAC8 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.